Prognostic and diagnostic value of plasma soluble suppression of tumorigenicity-2 concentrations in acute respiratory distress syndrome

Critical Care Medicine

Volumn 41, Issue 11, 2013, Pages 2521-2531

  Bajwa, Ednan K ^a   Volk, Jessica A ^a   Christiani, David C ^b   Harris, R Scott ^a   Matthay, Michael A ^c   Thompson, B Taylor ^a   Januzzi, James L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute respiratory distress syndrome; Biomarkers; Fluid therapy

Indexed keywords

BIOLOGICAL MARKER; SOLUBLE SUPPRESSION OF TUMORIGENICITY 2; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CARCINOGENICITY; CONCENTRATION (PARAMETERS); DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EMERGENCY CARE; FEMALE; FLUID THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC;

ADULT; APACHE; BIOLOGICAL MARKERS; COMORBIDITY; FEMALE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES;

EID: 84887030946     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182978f91     Document Type: Article

References (33)

1. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 2000; 342:1334-1349
2. Bull TM, Clark B, McFann K, et al; National Institutes of Health/National Heart, Lung, and Blood Institute ARDS Network: Pulmonary vascular dysfunction is associated with poor outcomes in patients with acute lung injury. Am J Respir Crit Care Med 2010; 182:1123-1128
3. Calfee CS, Eisner MD, Ware LB, et al; Acute Respiratory Distress Syndrome Network, National Heart, Lung, and Blood Institute: Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders. Crit Care Med 2007; 35:2243-2250
4. Calfee CS, Ware LB, Glidden DV, et al; National Heart, Blood, and Lung Institute Acute Respiratory Distress Syndrome Network: Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury. Crit Care Med 2011; 39:711-717
5. Ware LB, Koyama T, Billheimer DD, et al; NHLBI ARDS Clinical Trials Network: Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010; 137:288-296
6. Bajwa EK, Boyce PD, Januzzi JL, et al: Biomarker evidence of myocardial cell injury is associated with mortality in acute respiratory distress syndrome. Crit Care Med 2007; 35:2484-2490
7. Iwahana H, Yanagisawa K, Ito-Kosaka A, et al: Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 1999; 264:397-406
8. Schmitz J, Owyang A, Oldham E, et al: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479-490
9. Oshikawa K, Yanagisawa K, Tominaga Si, et al: ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem Biophys Res Commun 2002; 299:18-24
10. Brunner M, Krenn C, Roth G, et al: Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 2004; 30:1468-1473
11. Oshikawa K, Kuroiwa K, Tago K, et al: Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001; 164:277-281
12. Tajima S, Oshikawa K, Tominaga S, et al: The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 2003; 124:1206-1214
13. Hoogerwerf JJ, Tanck MW, van Zoelen MA, et al: Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med 2010; 36:630-637
14. Weinberg EO, Shimpo M, De Keulenaer GW, et al: Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002; 106:2961-2966
15. Seki K, Sanada S, Kudinova AY, et al: Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009; 2:684-691
16. Sabatine MS, Morrow DA, Higgins LJ, et al: Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008; 117:1936-1944
17. Pascual-Figal DA, Manzano-Fernández S, Boronat M, et al: Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: Complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011; 13:718-725
18. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, Bernard GR, et al: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354: 2564-2575
19. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al: The N-terminal Pro- BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95:948-954
20. The ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, et al: Acute respiratory distress syndrome: The Berlin Definition. JAMA 2012; 307:2526-2533
21. Knaus WA, Wagner DP, Draper EA, et al: The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100:1619-1636
22. Mehta RL, Kellum JA, Shah SV, et al; Acute Kidney Injury Network: Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31
23. Dieplinger B, Januzzi JL Jr, Steinmair M, et al: Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-The Presage ST2 assay. Clin Chim Acta 2009; 409:33-40
24. Youden WJ: Index for rating diagnostic tests. Cancer 1950; 3: 32-35
25. Liu KD, Thompson BT, Ancukiewicz M, et al; National Institutes of Health National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network: Acute kidney injury in patients with acute lung injury: Impact of fluid accumulation on classification of acute kidney injury and associated outcomes. Crit Care Med 2011; 39:2665-2671
26. Grams ME, Estrella MM, Coresh J, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network: Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol 2011; 6:966-973
27. Rehman SU, Mueller T, Januzzi JL Jr: Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008; 52:1458-1465
28. Ky B, French B, McCloskey K, et al: High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011; 4:180-187
29. Vlaar AP, Honselaar WB, Binnekade JM, et al: Diagnosing acute lung injury in the critically ill: A national survey among critical care physicians. Acta Anaesthesiol Scand 2009; 53:1293-1299
30. Schütte H, Lohmeyer J, Rosseau S, et al: Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. Eur Respir J 1996; 9:1858-1867
31. Bajwa EK, Januzzi JL, Gong MN, et al: Prognostic value of plasma N-terminal probrain natriuretic peptide levels in the acute respiratory distress syndrome. Crit Care Med 2008; 36: 2322-2327
32. Tajima S, Bando M, Ohno S, et al: ST2 gene induced by type 2 helper T cell (Th2) and proinflammatory cytokine stimuli may modulate lung injury and fibrosis. Exp Lung Res 2007; 33:81-97
33. Van Kimmenade RR, Januzzi JL Jr: Emerging biomarkers in heart failure. Clin Chem 2012; 58:127-138